E0C Stock Overview

A technology company, engages in developing software for the health and care sector. More details

E0C fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	2/6

Rewards

Trading at 37.1% below our estimate of its fair value

Earnings are forecast to grow 81.43% per year

Risk Analysis

Dividend of 8.14% is not well covered by earnings or free cash flows

My Notes

Capture your thoughts, links and company narrative

Carasent AB (publ) Competitors

MeVis Medical Solutions

XTRA:M3V

€44.4m

DocCheck

XTRA:AJ91

€41.9m

Nexus

XTRA:NXU

€1.2b

CompuGroup Medical SE KGaA

XTRA:COP

€1.1b

Price History & Performance

Summary of share price highs, lows and changes for Carasent
Historical stock prices
Current Share Price	SEK 1.91
52 Week High	SEK 1.92
52 Week Low	SEK 0.87
Beta	-0.68
1 Month Change	18.32%
3 Month Change	37.05%
1 Year Change	95.99%
3 Year Change	-50.52%
5 Year Change	n/a
Change since IPO	-11.40%

Recent updates

Shareholder Returns

	E0C	DE Healthcare Services	DE Market
7D	2.1%	1.2%	-2.0%
1Y	96.0%	-20.4%	6.9%

Return vs Industry: E0C exceeded the German Healthcare Services industry which returned -20.4% over the past year.

Return vs Market: E0C exceeded the German Market which returned 6.9% over the past year.

Price Volatility

Is E0C's price volatile compared to industry and market?
E0C volatility
E0C Average Weekly Movement	6.0%
Healthcare Services Industry Average Movement	6.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: E0C has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: E0C's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	169	Daniel Ohman	carasent.com

Carasent AB (publ), a technology company, engages in developing software for the health and care sector. It offers cloud based electronic health record systems solutions with Webdoc as a platform, and an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is based in Gothenburg, Sweden.

Carasent AB (publ) Fundamentals Summary

How do Carasent's earnings and revenue compare to its market cap?
E0C fundamental statistics
Market cap	€138.41m
Earnings (TTM)	-€671.67k
Revenue (TTM)	€22.41m

6.2x

P/S Ratio

-206.1x

P/E Ratio

Is E0C overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
E0C income statement (TTM)
Revenue	NOK 264.80m
Cost of Revenue	NOK 42.52m
Gross Profit	NOK 222.27m
Other Expenses	NOK 230.21m
Earnings	-NOK 7.94m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	-0.11
Gross Margin	83.94%
Net Profit Margin	-3.00%
Debt/Equity Ratio	0%

How did E0C perform over the long term?

See historical performance and comparison

Dividends

8.1%

Current Dividend Yield

-230%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 03:27
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carasent AB (publ) is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristofer Liljeberg-Svensson	Carnegie Commissioned Research
Ole-Andreas Krohn	DNB Markets
Christoffer Bjørnsen	DNB Markets

E0C Stock Overview

Rewards

Risk Analysis

Carasent AB (publ) Competitors

XTRA:M3V

€44.4m

XTRA:AJ91

€41.9m

XTRA:NXU

€1.2b

XTRA:COP

€1.1b

Price History & Performance

Recent News & Updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

Shareholder Returns

Price Volatility

About the Company

Carasent AB (publ) Fundamentals Summary